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Tumour cell-derived Wnt7a recruits and activates
ﬁbroblasts to promote tumour aggressiveness
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Stromal ﬁbroblast recruitment to tumours and activation to a cancer-associated ﬁbroblast
(CAF) phenotype has been implicated in promoting primary tumour growth and progression
to metastatic disease. However, the mechanisms underlying the tumour:ﬁbroblast crosstalk
that drive the intertumoural stromal heterogeneity remain poorly understood. Using in vivo
models we identify Wnt7a as a key factor secreted exclusively by aggressive breast tumour
cells, which induces CAF conversion. Functionally, this results in extracellular matrix
remodelling to create a permissive environment for tumour cell invasion and promotion of
distant metastasis. Mechanistically, Wnt7a-mediated ﬁbroblast activation is not dependent
on classical Wnt signalling. Instead, we demonstrate that Wnt7a potentiates TGFb receptor
signalling both in 3D in vitro and in vivo models, thus highlighting the interaction between two
of the key signalling pathways in development and disease. Importantly, in clinical breast
cancer cohorts, tumour cell Wnt7a expression correlates with a desmoplastic, poor-prognosis
stroma and poor patient outcome.
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F
ibroblasts constitute a signiﬁcant proportion of the stromal
compartment in many solid tumours and these inﬁltrating
cells can acquire an activated cancer-associated ﬁbroblast
(CAF) phenotype. There is now extensive evidence functionally
implicating CAFs in tumour progression via their ability to
deposit and remodel extracellular matrix components, secrete
pro-tumorigenic factors and modulate the immune compart-
ment1–5. In breast cancer this so-called ‘desmoplastic response’
shows a clinical correlation with invasion and poor patient
prognosis6. In addition, there is an increasing body of
data supporting a role of CAFs in promoting resistance to
chemotherapy and targeted agents7. Despite the growing interest
in the functional role of CAFs in tumours, much of their biology
remains a mystery because of the lack of speciﬁc markers, as well
as ﬁbroblast phenotypic plasticity and heterogeneity both in vivo
and in vitro8,9. Together, these have hampered efforts to
disentangle the mechanisms underlying tumour:ﬁbroblast
crosstalk that could reveal novel strategies for disrupting
stromal activation and thereby enhancing therapeutic targeting
of tumour cells. In particular, although it is well recognized
that CAF recruitment and activation are strikingly variable
between different breast cancers10–12, there is little understa-
nding of the mechanisms driving this intertumour stromal
heterogeneity.
The goal of this study was to identify the mechanisms that
underpin the differential inﬁltration and activation of CAFs in
breast cancer and to determine the relevance of these observa-
tions to human disease. By gene expression proﬁling of aggressive
and non-aggressive tumours, we identify Wnt7a as a key tumour
cell-secreted factor that promotes ﬁbroblast recruitment and
activation in three-dimensional (3D) in vitro assays and in vivo.
Mechanistically, Wnt7a does not signal through the classical Wnt
pathways to trigger CAF conversion but potentiates TGFb
receptor signalling. Interestingly, this promotion of TGFb
receptor signalling is dependent on dynamic reciprocity between
ﬁbroblasts and a malleable extracellular matrix. Functionally, high
Wnt7a expression in tumour cells promotes metastasis in vivo
and, in human breast cancers, correlates with a desmoplastic,
poor-prognosis stroma with high ﬁbroblast TGFb pathway
activation and reduced patient survival. We identify a novel level
of interaction between Wnt and TGFb pathways in CAFs, which
presents a potential avenue for inhibiting or reversing the
production of a tumour-promoting stroma.
Results
Stromal heterogeneity in a breast cancer progression model. In
this study we employed the 4T1 series of mouse mammary
carcinoma tumours as an in vivo model of breast cancer
progression. The 4T1 series cell lines have a single origin
but, despite all giving rise to primary tumours in syngeneic Balb/c
mice, differ in their metastatic potential13–15. To characterize
their in vivo stromal phenotypes, orthotopic tumours were
ﬁrst stained with the pan-ﬁbroblast marker endosialin16
and the ﬁbroblast activation marker aSMA. Strikingly, we
found that inﬁltrating aSMA-positive CAFs are abundant
in the metastatic 4T1 and 410.4, but not in the less aggressive
4T07 tumours (Fig. 1a and Supplementary Fig. 1a). As both
endosialin and aSMA are also expressed by tumour pericytes17,
sections were also stained with the endothelial marker
endomucin. The low incidence of endosialin-positive cells
associated with endomucin-stained blood vessels indicates that
the inﬁltrating endosialin-positive cells are predominantly of
ﬁbroblast identity (Supplementary Fig. 1b). As the goal of this
project was to interrogate tumour:stroma crosstalk in vivo, 4T1,
410.4 and 4T07 cells were inoculated orthotopically into Ub-GFP
Balb/c mice. This approach allowed tumour cell and CAF
populations to be isolated by FACSorting and directly lysed for
gene expression proﬁling (Fig. 1b). In concordance with
the histological data (Fig. 1a), we show that aggressive 4T1
tumours contain a signiﬁcantly higher proportion of CAFs
(GFPþ ; CD45 cells) as compared with the less aggressive
4T07 tumours (Fig. 1b). qPCR analysis of ﬁbroblast populations
conﬁrmed that CAFs from more aggressive breast tumours have
an ‘activated’ CAF phenotype as evidenced by the gradient
increase in expression of the myoﬁbroblast markers aSMA
(Acta2)2, transgelin (Tagln)18 and TGFb1 (Tgfb1)19–21 from
control mouse mammary gland ﬁbroblasts (MGFs) to 4T07
ﬁbroblasts to 410.4/4T1 ﬁbroblasts (Fig. 1c). To explore the cause
of this differential regulation, the gene expression proﬁles of the
tumour cells isolated from the less aggressive 4T07 tumours with
low-level CAF activation and from the more aggressive 410.4 and
4T1 tumours characterized by substantial CAF recruitment and
activation were interrogated. When subjected to hierarchical
clustering, the 4T07 tumour cells clearly separate away from 410.4
and 4T1 tumour cells (Fig. 1d). A pairwise comparison between
the two groups identiﬁed 3,406 differentially expressed genes,
with 498 probes showing a fold change 42. We hypothesized
that CAF recruitment and activation is, at least initially, driven by
paracrine signalling, and therefore the main focus of our further
investigations was differentially expressed soluble factors.
Functional annotation of the differentially expressed genes
identiﬁed 56 secreted factors that are more highly expressed by
410.4 and 4T1 tumour cells compared with 4T07 tumour cells
(Supplementary Table 1) and of potential interest for further
analysis.
Tumour cell-secreted Wnt7a promotes ﬁbroblast activation.
After bioinformatic analysis and extensive literature review,
we selected a range of tumour cell-secreted factors for further
investigation. qPCR validation using additional independently
FACSorted populations conﬁrmed that all selected factors
show lower expression in 4T07 compared with 410.4/4T1
tumour cell samples (Fig. 1e). Of note, we did not observe a
differential tumour cell expression of TGFb1, the secreted factor
most commonly associated with myoﬁbroblast conversion1,2
(Fig. 1e).
To assess the ability of these factors to promote ﬁbroblast
recruitment and activation in vivo, six targets were selected and
4T07 tumours were supplemented with the corresponding
recombinant proteins by intratumoural injection. Supplementa-
tion had no effect on tumour take, tumour growth (Fig. 2a) or
tumour weight at necroscopy (Supplementary Fig. 2a). As
observed in untreated tumours (Fig. 1a), vehicle-treated 4T07
tumours have few, if any, inﬁltrating CAFs and the peritumoural
ﬁbroblasts remain aSMA-negative (Fig. 2b and Supplementary
Fig. 2b). No differences are observed in the stromal compart-
ments of BMP-7, CXCL16 or granulocyte–macrophage colony-
stimulating factor (GM-CSF)-treated tumours (data not shown).
Dhh and PDGF-BB treatment results in increased ﬁbroblast
inﬁltration; however, the inﬁltrating ﬁbroblasts remain aSMA-
negative suggesting that these factors have some ability to
promote ﬁbroblast recruitment but not activation. PDGF-BB
treatment also stimulated a stromal angiogenic response (Fig. 2b).
Strikingly, Wnt7a (Supplementary Fig. 2c) was as effective as
TGFb1 treatment in generating 4T07 tumours containing a
substantial population of activated CAFs in the tumour core
(Fig. 2b). The observation that Wnt7a has no effect on ﬁbroblast
proliferation in vitro (Fig. 2c) indicates that the increase in
intratumoural ﬁbroblasts results from increased ﬁbroblast
recruitment and is not solely due to mitotic expansion.
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Figure 1 | Differential CAF recruitment and activation in vivo. (a) 4T07, 410.4 and 4T1 orthotopic tumours in Balb/c mice were formalin-ﬁxed and
parafﬁn-embedded and sections stained with FITC–aSMA (green) and endosialin followed by Alexa 555-anti-rabbit-IgG (red). Nuclei were counterstained
with 4,6-diamidino-2-phenylindole (DAPI; blue). Representative confocal images are shown. Dashed line indicates the border between tumour, T, and
stroma, S. Scale bar, 75mm. Low-power images are shown in Supplementary Fig. 1a. (b) Isolation of tumour cells and CAFs. 4T07, 410.4 and 4T1 cells were
inoculated into the fourth mammary fat pad of Ub-GFP Balb/c mice. Confocal images of 4T1 and 4T07 tumours showing GFP-negative tumour cells and
GFP-positive stromal cells. Scale bar, 25 mm. Tumours were dissociated and subject to FACSorting. Shown are representative FACS proﬁles from 4T1 and
4T07 tumours. Right panel shows the number of GFPþ ; CD45 ﬁbroblasts as a percentage of live cells in individual 4T07 (n¼ 14) and 4T1 (n¼ 7)
tumours. Comparison made using Student’s t-test. (c,d) Tumour cells and ﬁbroblasts from three independent isolates were directly lysed for RNA
extraction. (c) Acta2, Tagln and Tgfb1 mRNA expression in normal MGFs and CAFs monitored using qPCR. Data shown are the mean±s.e.m. relative
quantiﬁcation (RQ) values from three independent biological replicates. (d) Tumour cells were subject to whole-genome expression proﬁling. Dendrogram
shows correlation-centred hierarchical clustering based on average linkage. Shown are tumour cell expression data of probes signiﬁcantly differentially
expressed between 410.4/4T1 and 4T07 tumour cells with a fold change 42 (498 probes). (e) qPCR validation of selected genes from independently
FACSorted tumour cell samples. n, non-detectable. Data shown are the mean±s.e.m. RQ values from three independent biological replicates.
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While our data show that aggressive tumour cells secrete
Wnt7a, we next sought to determine whether there are other
sources of Wnt7a within the tumour. qPCR analysis of different
cell populations freshly isolated from the tumours demonstrates
that indeed aggressive tumour cells are the principal sources of
Wnt7a, with little or no expression detected in CAFs, immune cell
populations or less aggressive 4T07 tumour cells (Fig. 2d).
Next, to assess the effect of manipulating tumour cell Wnt7a
expression levels on the ﬁbroblast compartment in vivo, CAF
recruitment was assessed in tumours generated by orthotopic
inoculation of 4T07 cells ectopically expressing Wnt7a
(4T07-Wnt7a; Fig. 3a and Supplementary Fig. 3a). Compared
with 4T07 cells infected with vector alone (4T07-Vec),
4T07-Wnt7a tumours show a signiﬁcantly increased inﬁltration
of activated CAFs into the tumour core, equivalent to that
observed in 4T1 tumours. Finally, we extended this analysis to a
non-metastatic member of the 4T1 cell line series, 168FARN
(refs 13–15), and a human breast cancer cell line, ZR75.1. In both
cases, ectopic expression of Wnt7a promotes a signiﬁcant increase
in recruitment of aSMA-positive CAFs (Fig. 3b,c and
Supplementary Fig. 3b,c).
Finally, we tested whether the in vivo functional CAF
conversion triggered by Wnt7a could be recapitulated in an
in vitro assay. Increased ﬁbroblast contractility is a major
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Figure 2 | Wnt7a promotes ﬁbroblast recruitment and activation in vitro and in vivo. (a,b) 4T07 cells were injected bilaterally into the fourth mammary
fat pads of wild-type Balb/c mice (four to ﬁve mice per group) and treated with recombinant growth factors (see Methods section). (a) Data represent the
mean tumour volume±s.e.m. (see Supplementary Fig. 2a for tumour weights). Groups were compared with two-way ANOVA followed by Bonferroni
post-test. No statistically signiﬁcant differences were found. (b) Tumours were stained for aSMA-FITC (green) and endosialin followed by Alexa 555-anti-
rabbit-IgG (red). Nuclei were counterstained with DAPI (blue). Representative confocal images are shown. T, tumour; S, stroma; arrowheads, peritumoural
blood vessels. Scale bar, 150 mm. See Supplementary Fig. 2b for separated images. (c) NF#1 ﬁbroblasts were treated with vehicle or 100ngml 1 Wnt7a and
viable cell amount monitored by CellTiter-Glo assay at the indicated time points. Data represent the mean values from four wells per condition at each time
point±s.e.m. (d) Tumour (GFP ; CD45 ), immune cell (GFPþ ; CD45þ ) and CAF (GFPþ ; CD45 ) populations from 4T1, 410.4 and 4T07 tumours.
Wnt7a mRNA expression was monitored using qPCR as described in b. n, non-detectable. Data shown are the mean±s.e.m. RQ values from two
independent biological replicates.
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hallmark of CAF conversion and can be readily monitored
by contraction of ﬁbroblast-containing 3D collagen gels22.
Treatment with either recombinant Wnt7a or conditioned
medium from 4T07 cells ectopically expressing Wnt7a, but not
conditioned medium from 4T07 cells transfected with vector
alone, signiﬁcantly enhanced normal ﬁbroblast contractility
(Fig. 3d). Moreover, ﬁbroblasts ectopically expressing Wnt7a
were more contractile than control ﬁbroblasts expressing empty
vector alone (Fig. 3e).
Together, these data highlight Wnt7a as a novel and highly
potent tumour cell-secreted factor that is sufﬁcient to drive
conversion of ﬁbroblasts into CAFs within the tumour micro-
environment. We next investigated the underlying paracrine
signalling events to better understand the molecular mechanisms
of action of Wnt7a.
Wnt7a-driven CAF conversion is TGFb-signalling-dependent.
Wnt7a has been demonstrated to play a role in develo-
pment23–25, regeneration26, muscle satellite and neural27,28 stem
cell expansion and malignant transformation29,30, underlining
the importance of this Wnt family member in a multitude of
biological processes. At the molecular level, Wnt7a has been
implicated in both b-catenin-dependent29,31 and b-catenin-
independent32,33 signalling, determined by cell and tissue
context. To interrogate the Wnt7a signalling pathways
operating in CAF activation, we used both immortalized NF#1
mouse MGFs and NIH-3T3 ﬁbroblasts. Using cells plated on
tissue culture plastic, we ﬁrst assessed the activation of
b-catenin-dependent Wnt signalling in response to Wnt7a.
While, as expected, the GSK-3b inhibitor SB216763 or Wnt3a, a
known inducer of b-catenin-dependent Wnt signalling, results
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Figure 3 | Wnt7a promotes ﬁbroblast recruitment and activation in vivo and in vitro. Quantiﬁcation of aSMA staining in primary tumours following
ectopic expression of Wnt7a (see Supplementary Fig. 3 for qPCR analysis). Left panels show quantiﬁcation of aSMA staining. Right panels show
representative images of aSMA staining. (a) Balb/c mice inoculated with 5 105 parental 4T1, parental 4T07, vector-transfected 4T07 (4T07-Vec) and
4T07-expressing Wnt7a (4T07-Wnt7a) cells. Tumours were removed on day 30. Tumour numbers; 4T1, n¼ 5; 4T07, 4T07-Vec, 4T07-Wnt7a, n¼ 9 or 10.
Scale bar, 100 mm. (b) Balb/c mice inoculated with 3 106 168FARN-Vec or 168FARN-Wnt7a cells. Tumours were removed on day 12. Data shown are from
ﬁve mice per group. Scale bar, 100mm. (c) 2 106 ZR75.1-Vec and ZR75.1-Wnt7a were inoculated into nonobese diabetic severe combined
immunodeﬁcient mice. Tumours were removed on day 28. Data shown are from four mice per group. Scale bar, 50mm. (d) NF#1 MGFs embedded in
collagen gels were treated with BSA or Wnt7a (100 ngml 1) or conditioned medium from 4T07 cells transfected with vector alone (4T07-Vec CM) or
Wnt7a (4T07-Wnt7a CM) for 72 h. Data show quantiﬁcation of matrix remodelling as monitored by gel contraction±s.e.m. Equivalent results were
obtained in three independent experiments (e) NIH-3T3 ﬁbroblasts expressing empty vector (3T3-Vec) or Wnt7a (3T3-Wnt7a) were assayed as described
in d. All comparisons were made using Student’s t-test.
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in a robust translocation of b-catenin into the nucleus, Wnt7a
did not activate this pathway in either NF#1 or NIH-3T3
(Supplementary Fig. 4a) ﬁbroblasts. Similar results were
obtained using the TOPﬂash Wnt reporter assay
(Supplementary Fig. 4b). Next, to assess whether Wnt7a
signals through either of the b-catenin-independent Wnt
signalling pathways, the activation of key pathway
components was examined using western immunoblot
analysis. Strikingly, there was no evidence that Wnt7a
activates either Wnt/Ca2þ or planar cell polarity signalling as
monitored by CaMKII phosphorylation or c-Jun
phosphorylation, respectively (Supplementary Fig. 4c).
Importantly, in contrast to the ability of Wnt7a to drive
ﬁbroblast activation in vivo (Figs 2 and 3a–c) and in
3D collagen gels (Fig. 3d,e), we were unable to detect a
Wnt7a-mediated increase in the aSMA expression in ﬁbroblasts
plated on rigid, nonphysiological tissue culture plastic (data not
shown), suggesting that Wnt7a-mediated CAF conversion acts
in concert with ﬁbroblast mechanosensing. To address this, we
established a more physiologically relevant model in which
ﬁbroblasts are plated on extracellular matrix-coated synthetic
hydrogels. In this setting we are able to recapitulate a
phenotypic Wnt7a-mediated CAF conversion of NF#1 and
NIH-3T3 ﬁbroblasts as assessed by increased aSMA levels and
localization of aSMA into characteristic stress ﬁbres (Fig. 4a).
However, when plated on hydrogels, we again observe no
activation of b-catenin, Ca2þ -dependent or planar cell polarity
Wnt signalling pathways (Fig. 4b,c).
To date, the pathway most frequently implicated in
extracellular matrix mechanosensing and myoﬁbroblast differ-
entiation is TGFb signalling2,34–36. Therefore, we investigated
next whether there is an interplay between Wnt7a and
TGFb signalling during ﬁbroblast activation. In classical
TGFb signalling, TGFb binding to a target cell results in
phosphorylation of Smad2 and Smad3 and their translocation
into the nucleus where they trigger transcriptional activation of
target genes including aSMA. Indeed, in both NFx1 (Fig. 5a,b)
and NIH-3T3 (Supplementary Fig. 5a,b) ﬁbroblasts plated in 3D
collagen gels, the Wnt7a-dependent increase in ﬁbroblast
contractility is accompanied by efﬁcient nuclear translocation of
phosphorylated Smad2. Moreover, treatment with the TGFb type
I receptor (TbR1; ALK5) inhibitor SB431542 not only effectively
blocked Wnt7a-mediated phospho-Smad2 nuclear translocation
but also Wnt7a-mediated ﬁbroblast contraction (Fig. 5a,b and
Supplementary Fig. 5a,b). Further, ALK5 inhibition also
effectively blocked the enhanced ﬁbroblast contractility in 3D
collagen gels following treatment with conditioned medium from
4T07 cells ectopically expressing Wnt7a (Fig. 5c). Similarly, the
enhanced contractile force that NFx1 (Fig. 5d) and NIH-3T3
(Fig. 5e) ﬁbroblasts ectopically expressing Wnt7a exert on the
extracellular matrix, as monitored by 3D collagen gel contraction
(left panels) and a locally increased density of collagen ﬁbrils
(right panels), was completely blocked by the ALK5 inhibitor
SB431542.
These data support a model in which Wnt7a, in a manner that
is dependent on malleability of the mechanical substrate,
potentiates TGFb receptor signalling and that this potentiation
of TGFb receptor activity is critical for myoﬁbroblast conversion.
In support of this model, ﬁbroblasts associated with 4T1 tumours
show a signiﬁcantly increased TGFb pathway activation com-
pared with 4T07 tumour ﬁbroblasts as monitored by higher
phospho-Smad2 levels within the ﬁbroblast nuclei (Fig. 5f).
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Figure 5 | Wnt7a and TGFb pathways converge during myoﬁbroblast conversion. (a) NF#1 ﬁbroblast matrix remodelling assay. NF#1 ﬁbroblasts embedded
in collagen gels were treated with BSA, Wnt7a or TGFb1 in the presence or absence of SB43152 for 72h. Recombinant Wnt7a was pre-absorbed with a
neutralizing anti-TGFb antibody before use (see Methods). Data show quantiﬁcation of matrix remodelling by NF#1 ﬁbroblasts±s.e.m. Groups were compared
using two-way ANOVA followed by Bonferroni post-test. ***Po0.001. Equivalent results were obtained in two independent experiments. (b) Remodelled gels
from a were ﬁxed, sectioned and stained with antibodies against the pan-ﬁbroblast marker Endo180 (Mrc2) (red) and phospho-Smad2 (green). Nuclei were
counterstained with DAPI. Left panel, the mean ﬁbroblast phospho-Smad2 scores±s.e.m. (n¼ 3 remodelled gels in each group). One-way ANOVA with
Bonferroni post-test was used to compare groups. **Po0.01. Right panel, representative images. Scale bar, 150mm. (c) NF#1 ﬁbroblasts embedded in collagen
gels were treated with conditioned medium from 4T07 cells transfected with vector alone (4T07-Vec CM) or Wnt7a (4T07-Wnt7a CM) in the presence or
absence of SB43152 (10mM) for 72h. Conditioned media were pre-absorbed with a neutralizing anti-TGFb antibody before use (see Methods). Data show
quantiﬁcation of matrix remodelling±s.e.m. Two-way ANOVA with Bonferroni post-test was used to compare groups. ***Po0.001. (d,e) NF#1 or NIH-3T3
ﬁbroblasts transfected with vector alone (Vec) or Wnt7a (Wnt7a) embedded in collagen gels were cultured in the presence or absence of SB43152 (10mM).
Data show quantiﬁcation of matrix remodelling from ﬁve independent experiments±s.e.m. Groups were compared using two-way ANOVA. **Po0.01.
Representative confocal images of NF#1 and NIH-3T3 gels stained with TRITC-phalloidin (red) and second-harmonic emission to image collagen density (green).
Scale bar, 20mm. (f) 4T1 and 4T07 tumour sections were stained for Endo180 (Mrc2) (red) and phospho-Smad2 (green). Nuclei were counterstained with DAPI.
Left panel, representative images taken from the tumour–stroma interface. Arrowheads indicate Endo180-positive ﬁbroblasts with high nuclear phospho-Smad2.
Scale bar, 50mm. Right panel, the mean ﬁbroblast phospho-Smad2 scores (n¼ 5 tumours in each group). Comparison was made using Student’s t-test.
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Wnt7a-activated CAFs promote invasion and metastasis. In
light of our ﬁndings that Wnt7a promotes an altered stromal
compartment in aggressive tumours, we next characterized the
functional properties of Wnt7a-activated CAFs. In organotypic
assays in which tumour cells are plated on a 3D matrix containing
live ﬁbroblasts, Wnt7a treatment signiﬁcantly enhances tumour
cell invasion (Fig. 6a). Importantly, in a complementary approach
where Wnt7a-treated ﬁbroblasts are allowed to remodel the 3D
matrix but are killed before tumour cell invasion is assessed, we
demonstrate that the increased tumour cell invasion is dependent
on the ability of the treated ﬁbroblasts to remodel the matrix
(Fig. 6b). Importantly, the ability of Wnt7a-activated ﬁbroblasts
to promote tumour cell invasion is effectively blocked by
the ALK5 inhibitor SB421542 (Fig. 6), further supporting
a mechanism in which Wnt7a promotes the functional
differentiation of ﬁbroblasts into activated CAFs in a TGFb
signalling-dependent manner.
Two complementary approaches were taken to investigate the
role of Wnt7a in promoting tumour aggressiveness of in vivo
breast cancer models. First, the effect of short hairpin RNA
(shRNA)-mediated downregulation of Wnt7a expression was
assessed in a spontaneous metastasis assay. Targeting Wnt7a with
either of two independent shRNAs (Supplementary Fig. 6a) has
no effect on primary tumour growth (Fig. 7a) but results in an
overall trend to decreased aSMA and ﬁbroblast activation protein
(FAP) expression by tumour ﬁbroblasts (Supplementary Fig. 6b).
Importantly, this impairment in CAF activation correlates with a
signiﬁcant reduction in spontaneous metastasis to the lung
(Fig. 7a). In addition, Wnt7a downregulation signiﬁcantly impairs
TGFb pathway activation in the CAFs as monitored by the
reduced levels of phospho-Smad2 detected within ﬁbroblast
nuclei (Fig. 7b), demonstrating that the same signalling pathways
are active both in vitro and in vivo. Second, in an experimental
metastasis assay, ectopic expression of Wnt7a in the less
aggressive 4T07 cells signiﬁcantly enhances metastatic lung
colonization as monitored by ex vivo lung weight and histological
quantiﬁcation (Fig. 7c).
Wnt7a correlates with stromal dysplasia and poor prognosis.
Consistent with our ﬁndings in mouse mammary tumours
(Fig. 2d), in human breast cancers Wnt7a protein expression is
predominantly associated with the tumour cell compartment,
with lower levels detectable within the stroma (Supplementary
Fig. 7). To address the clinical signiﬁcance of Wnt7a expression
in tumours, we ﬁrst examined whether Wnt7a expression in
human breast cancer correlates with a desmoplastic stroma.
Immunohistochemical staining of an initial set of 65 human
invasive breast cancers revealed an increased CAF activation in
tumours with high Wnt7a expression (Fig. 8a). These ﬁndings
were then extended to a larger, independent cohort of 347 breast
cancers11. Consistent with the initial set, tumours expressing
high levels of Wnt7a have a signiﬁcantly increased desmoplastic
response (Fig. 8b), characterized by more numerous
aSMA-positive CAFs (P¼ 0.0576) as well as increased aSMA
levels in the recruited CAFs (P¼ 0.0009; Supplementary Fig. 8a).
Second, taking a complementary approach, we examined the
ﬁbroblast core serum response (F-CSR) signature described
in ref. 37 as a surrogate measure of CAF activation in clinical
data sets, and demonstrated a signiﬁcant correlation between
high WNT7A expression in human breast cancers and a high
F-CSR score (P¼ 2.56 10 5; Supplementary Fig. 8b). In
addition, in agreement with our in vitro and in vivo data,
using the ﬁbroblast TGFb response signature (F-TBRS)
described in ref. 38, we also show a signiﬁcant correlation
between high WNT7A expression and a high F-TBRS score
(P¼ 0.005; Supplementary Fig. 8c), further supporting the
convergence of Wnt7a and TGFb signalling pathways to drive
ﬁbroblast activation.
To examine the clinical signiﬁcance of these ﬁndings we used
three different approaches. First, examination of levels of Wnt7a
protein expression in the 347 breast cancer cohort (Fig. 8b)
revealed that overall patient survival is signiﬁcantly reduced in
the Wnt7a high versus the Wnt7a low group (P¼ 0.0273
log-rank test; Fig. 8c), and that, by multivariate analysis, Wnt7a
expression is an independent prognostic outcome marker
(Fig. 8d). Second, we performed unsupervised hierarchical
clustering of the Finak et al.39 stroma-derived prognostic
predictor (SDPP) genes and WNT7A in The Cancer Genome
Atlas (TCGA) primary breast cancer data set and demonstrated
that WNT7A clusters with the SDPP poor prognostic genes
(Fig. 8e). Further, Pearson correlation shows that there is a
signiﬁcant association between WNT7A gene expression and the
gene expression centroid of the SDPP poor prognostic group
(r¼ 0.213, Po0.0001). Finally, examination of WNT7A gene
expression in the TCGA breast cancer data set demonstrated an
increased Wnt7a expression in primary tumours versus matched
normal tissue (paired t-test P¼ 0.0098) and that within primary
tumours highWNT7A gene expression is signiﬁcantly associated
with basal-like breast cancer (one-way analysis of variance
(ANOVA), Po0.0001; Fig. 8f). High WNT7A expression is also
associated with ER versus ERþ tumours (unpaired t-test for
unequal s.d. with Welch’s correction, P¼ 0.0002), triple-
negative versus non-triple-negative tumours (unpaired t-test
for unequal s.d. with Welch’s correction, P¼ 0.0031) and
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Figure 6 | Wnt7a-driven myoﬁbroblast conversion increases tumour cell
invasion. (a) Organotypic assays of breast cancer cell invasion into NF#1
ﬁbroblast-containing matrix. Left panel: quantiﬁcation of invasion index
(a.u.) by measuring the total area over which cancer cells had dispersed
(including invading and non-invading cells) and the area of non-invading
cells. The value shown is the average 1—(non-invading area/total area) of
at least 13 measurements±s.e.m. Right panel, representative images used
for invasion index measurements. Scale bar, 50mm. Two-way ANOVA with
Bonferroni post-test used to compare groups. ***Po0.001. Equivalent
results were obtained in two independent experiments. (b) Organotypic
assays of cell invasion into a NF#1 ﬁbroblast-conditioned matrix. Left panel:
quantiﬁcation of invasion index (a.u.) and statistical analysis as in a for
seven measurements per gel±s.e.m. Right panel: representative images
used for invasion index measurements. Scale bar, 50mm. Two-way ANOVA
with Bonferroni post-test used to compare groups. **Po0.01. Equivalent
results were obtained in two independent experiments.
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primary tumours versus matched normal tissue (n¼ 22 pairs;
paired t-test, P¼ 0.0013). Importantly, consistent with the tissue
microarray (TMA) analysis presented here, there is a signiﬁcant
correlation between high WNT7A gene expression and poor
outcome (distant metastasis-free survival) in breast cancer
patients, either when examining all systemically untreated
breast cancers (log-rank P¼ 0.0382; Fig. 8g) or only the basal
breast cancers (log-rank, P¼ 0.0427; Fig. 8h).
Discussion
The main aim in this study was to identify the mechanisms
underlying the striking heterogeneity in stromal composition
between different breast tumours. We demonstrate that the
4T1 tumour cell line series recapitulates human disease in
showing a strong correlation between a desmoplastic response
and tumour aggressiveness, and making it a valid model for
studying heterogeneity of the CAF compartment in vivo. While
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others40–42 have performed gene expression proﬁling of 4T1
series tumours, our study is the ﬁrst to interrogate the puriﬁed
tumour cell and ﬁbroblast populations separately and to overlay
the data to uncover previously unknown players in the reciprocal
signalling between tumour cells and their associated CAFs. Using
this model we identiﬁed Wnt7a as a novel factor secreted by
aggressive tumour cells that drives the acquisition of a
desmoplastic response characterized by an activated CAF
phenotype, which is capable of matrix remodelling and
promotion of tumour cell invasion. Our ﬁndings also support a
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role for Wnt7a in the recruitment of a desmoplastic stroma in
human tumours, whereby high Wnt7a expression is associated
with enhanced CAF activation, TGFb pathway activation within
the CAF compartment and expression of poor-prognosis stromal
genes as deﬁned by the Finak et al.39 SDPP. Most importantly,
high Wnt7a expression is associated with reduced overall and
metastasis-free breast cancer patient survival. While this is the
ﬁrst report of Wnt7a as a prognostic marker in breast cancer,
Wnt7a has been documented to be upregulated in malignant as
compared with borderline or benign ovarian tumours and to
promote tumour growth in in vivo ovarian cancer models30.
In interrogating the mechanism by which Wnt7a promotes
ﬁbroblast activation, our studies have provided evidence that
implicates Wnt7a as a modulator of TGFb signalling. The
convergence of TGFb and Wnt signalling in both development
and disease has been documented previously; however, the
intricacies of this interaction are complex and clearly dependent
on the particular TGFb and Wnt family ligand as well as cell and
tissue context43. To date, the majority of reports have focused on
the convergence of Wnt and TGFb signalling at the level of their
respective downstream pathways, for example, the association of
Smads and LEF-1 or, more indirectly, by Wnt-mediated
transcriptional upregulation of TGFb family ligands and vice
versa44. Recent studies in mesenchymal cells have attributed the
signalling interaction between Wnt5a and TGFb to the activation
of Wnt-mediated Ca2þ and JNK, but not b-catenin, pathways45,
while others have reported that b-catenin-dependent Wnt
signalling is necessary for TGFb-mediated ﬁbrosis46. In our
study, we ﬁnd no evidence that Wnt7a promotes b-catenin
signalling or activates the CaMKII or planar cell polarity
pathways in ﬁbroblasts. Rather, our data support a model in
which a complete myoﬁbroblast conversion requires Wnt7a-
mediated potentiation of TGFb receptor activity and we suggest,
less traditionally, that this occurs at the level of the TGFb receptor
rather than via downstream signalling components. Interestingly,
it has recently been reported that Wnt5a expression is required to
potentiate TGFb signalling during colonic epithelial wound repair
and that, in a similar manner to that reported here, these effects
were dependent on TbR1 kinase activity, as evidenced by their
blockade following ALK5 inhibition26. The authors have
proposed that this interaction may provide a mechanism for
Wnt5a to regulate the localization and timing of TGFb signalling
during stem cell proliferation47. Such a model is consistent with
our observation that 4T07 and 4T1/410.4 tumour cells isolated
from in vivo orthotopic tumours did not differ in their TGFb
expression, yet the tumours displayed striking differences in
stromal composition, which is characterized by TGFb signalling
activation. Therefore, Wnt7a may be regulating the intricacies of
the location and timing of TGFb signalling. Indeed, FACSorted
CAFs from Wnt7a high 410.4/4T1 tumours consistently show
higher levels of Tgfb1 expression as compared with Wnt7a low
4T07 tumours (Fig. 1c). TGFb is well known to have the capacity
to act in an autocrine manner, and it is therefore tempting to
speculate that Wnt7a could lead, over the longer term, to the
establishment of a self-sustaining autocrine TGFb signalling loop
that maintains CAF activation.
As the regulatory mechanisms of TGFb signalling are
extremely complex48 and context-dependent, the molecular
nature of TbRI activation could be manifold. The potentiation
of TbRI kinase signalling could be mediated directly by the
interaction with a Wnt7a receptor component. For example, it
has recently been reported that Wnt ligands bound to the
LRP5/6 co-receptors physically interact with both TbR1 and
PDGFRb in mesenchymal cells49 and that the Ror2 co-receptor
is responsible for Wnt5a-mediated activation of TGFb signalling
in colonic epithelial stem cells26. Alternatively, Wnt7a could
interact indirectly with TbR1 via its association with other
transmembrane receptors. For example, Wnt7a bound to
Frizzled-7 has been demonstrated to associate with syndecan-4
and that binding of this receptor complex to ﬁbronectin is
required to drive symmetric expansion of satellite stem cells in
regenerative myogenesis27. Although there are no reports of
syndecan-4 binding to TbR1, syndecan-4 can trap TGFb1 on the
cell surface50, bringing it closer to its receptor and thus
providing a potential indirect mechanism linking Wnt7a to
TbR1. It is tempting to speculate that, if the same pathways are
active in ﬁbroblasts, this would lead to an autocrine signalling
loop that stabilizes the ﬁbroblast activation state within
tumours. In conclusion, our ﬁndings highlight a novel level of
interaction between Wnt and TGFb pathways—two of the key
signalling players in both development and disease. Disruption
of this interaction may be a promising strategy to disrupt
tumour:stroma crosstalk to prevent CAF recruitment or to break
autocrine CAF signalling loops, thereby reversing the
production of a pro-tumorigenic activated stroma.
Methods
Antibodies. Sources and dilutions used for the following antibodies are as follows.
aSMA (clone 1A4, A5228, Sigma; 1:2,000 for immunoblotting (IB), 1:500 for
immunohistochemistry), aSMA-ﬂuorescein isothiocyanate (FITC; clone 1A4;
F3777, Sigma; 1:1,000 for immunoﬂuorescence (IF)), phospho-CaMKII (Thr286;
D21E4, 12716, Cell Signaling, 1:1,000), b-catenin (14, BD Biosciences, 1:500 for
IB), phospho-b-catenin (9566, Cell Signaling, 1:1,000 for IB), CD45-PE-Cy5
(30-F11, BD Pharmingen, 1:100 for FACS), endomucin (V.7C7, Santa Cruz
Biotechnology, 1:1,000 for IF), endosialin (P13, see (ref. 51), 1:2,000 for IF),
Endo180 (Mrc2; AF4789, R&D Systems, 1:100 for IF), FAP (ab28244, Abcam,
1:100 for IF), c-Jun (60A8, 9165, Cell Signaling, 1:1,000 for IB), phospho-c-Jun
(54B3, Cell Signaling, 1:1,000 for IB), TGFb (1D11 neutralizing antibody, R&D
Systems), SAPK/JNK (9252, Cell Signaling, 1:1,000 for IB), phospho-SAPK/JNK
(9251, Cell Signaling, 1:1,000 for IB), phospho-Smad2 Ser465/467 (3101, Cell
Signaling, 1:100 IF), a-tubulin (B-5-1-2, Sigma, 1:25,000 for IB), vinculin
(E1E9V, 13901, Cell Signalling, 1:2,000 for IB), Wnt7a (ab100792, Abcam, 1:200
Figure 8 | Tumour Wnt7a expression correlates with breast cancer stromal activation and patient outcome. (a) A tissue microarray comprising 65
scoreable invasive breast cancers and 5 normal breast samples was assessed for Wnt7a and aSMA expression using immunohistochemistry. Shown are
representative 0.6-mm cores with low or high tumour cell Wnt7a expression, and the matched aSMA-stained cores. Graph shows correlation of Wnt7a
expression with the ‘ﬁbroblast activation score’ (see Methods section). (b) Assessment of Wnt7a protein expression and ﬁbroblast activation in an
independent (Leeds) tissue microarray comprising 347 scoreable breast tumours using the same scoring criteria as in a. (c) Kaplan–Meier curve showing
Wnt7a high protein expression in the Leeds samples was signiﬁcantly associated with decreased overall survival (P¼0.0273, log-rank Mantel–Cox).
(d) Cox multivariate analysis showing that Wnt7a expression in the Leeds samples is a signiﬁcant predictor of overall survival independent of oestrogen
receptor (ER), grade and lymph node (LN) status. Hazard ratios with 95% conﬁdence intervals (CIs) are shown. (e) Correlation of WNT7A expression with
the Finak SDPP. Unsupervised hierarchical clustering of the SDPP genes and WNT7A was performed with the 522 primary breast cancers available in the
TCGA data set. WNT7A was clustered with the poor-prognosis SDPP genes. Pearson correlation showed a signiﬁcant correlation between WNT7A
expression with centroid gene expression of the SDPP poor-prognosis group (r¼0.213, Po0.0001). (f) WNT7A expression was examined in the TCGA
data set of breast cancers (n¼ 514). Using one-way ANOVA and Tukey’s multiple comparison test, high WNT7A gene expression was signiﬁcantly
associated with the basal-like intrinsic subtype (Po0.0001). (g,h) Kaplan–Meier curves showing high WNT7A expression in 533 systemically untreated
breast cancers57, and the 73 systemically untreated basal breast cancers is signiﬁcantly associated with poor distant metastasis-free survival (P¼0.0382
and P¼0.0427, log-rank Mantel–Cox, respectively).
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for immunohistochemistry), Alexa-conjugated secondary antibodies (Invitrogen,
1:1,000 dilution), horseradish peroxidase (HRP)-conjugated secondary antibodies
(Jackson ImmunoResearch 1:5,000 for IB or Santa Cruz Biotechnology 1:10,000 for
IB). TRITC-phalloidin (Sigma P1951, 1:500 for IF). Uncropped immunoblots are
shown in Supplementary Fig. 9.
Reagents. Recombinant growth factors were as follows: BMP-7, CXCL16, Dhh,
GM-CSF, PDGF-BB, TGFb1, Wnt3a and Wnt7a (R&D Systems). SB431542
TGFbR1 inhibitor (10mM) and SB216763 GSK-3b inhibitor (10 mM) are both from
Tocris; ﬁbronectin, human plasma are from (341635) Calbiochem and Protein
G Dynabeads (10003D) from Life Technologies).
Gene expression proﬁling of cell populations from tumours. All animal work
was carried out with UK Home Ofﬁce approval. Overall, 5 105 4T1, 410.4 or
4T07 tumour cells suspended in 50 ml of a 1:1 mixture of PBS and growth
factor-reduced Matrigel were injected into the fourth mammary fat pad of
6–8-week-old female wild-type Balb/c or Ub-GFP Balb/c mice (Balb/c mice
expressing GFP under the human ubiquitin C promoter)52.
For isolation of tumour cells and ﬁbroblasts, primary tumours in Ub-GFP
Balb/c mice were removed at an average diameter of 10mm, homogenized using a
McIlwain Tissue Chopper (Campden Instruments) and digested in L-15 medium
containing 3mgml 1 collagenase type I at 37 C for 1 h, followed by digestion
with 0.025mgml 1 DNase at 37 C for 5min. After erythrocyte lysis using Red
Blood Cell Lysing Buffer (Sigma), single cells were resuspended at 1–2 107 cells
per ml in PBS and stained with CD45-PE-Cy5 and 4,6-diamidino-2-phenylindole
for FACSorting using a FACSAria ﬂow cytometer (BD Biosciences). Sorted cells
were pelleted and directly lysed in TRIzol (Invitrogen) for RNA extraction. RNA
was analysed using the RNA 6000 Nano kit on a 2100 BioAnalyser (Agilent), and
only samples with an RNA integrity number 49 were used for further
experiments.
For each tumour cell and ﬁbroblast population, 100 ng of RNA from three
independent biological replicates was ampliﬁed using the TotalPrep 96-RNA
ampliﬁcation kit from Ambion (Applied Biosystems). cRNA (1.6 mg) was
hybridized to the MouseWG-6 v2.0 Expression BeadChip (Illumina). Expression
data were analysed in R (www.bioconductor.org), using the lumi package for probe
selection. Data were transformed using variance stabilization and normalized using
quantile normalization. Pairwise comparisons were carried out using the limma
package. False discovery rate was used to correct for multiple testing. When
different sample groups were pooled for pairwise comparison, the replicates of the
different groups were considered replicates of a single group. Data for heatmap
presentation were prepared in Cluster 3.0, and the heatmaps were generated using
Java Treeview. Database for Annotation, Visualization and Integrated Discovery
(DAVID) v6.7 (National Institute of Allergy and Infectious Diseases) was used for
functional annotation analyses. Microarray data have been deposited in NCBI
Gene Expression Omnibus (GSE50471).
Cell culture and assays. ZR75.1 cells were obtained from American Type Culture
Collection and short tandem repeat tested every 4 months using the StemElite ID
System (Promega). Generation of the NF#1 ﬁbroblasts (immortalized normal
mouse mammary ﬁbroblasts) have been described previously22. In brief, ﬁbroblasts
from 8–10-week-old female FVB/n mice were cultured in DMEM plus 10% FCS
(fetal calf serum) and 1% ITS (insulin–transferrin–selenium; Invitrogen)
supplement and media changed daily. After expansion in culture, ﬁbroblasts were
immortalized by infection with HPV-E6 retrovirus and selected using 2.5 mgml 1
puromycin.
NIH-3T3 ﬁbroblasts were from Isacke Laboratory stocks. 4T1 series cell lines
were Sahai Laboratory stocks. Cells were maintained in DMEM plus 10% FCS in
tissue culture-treated plastic or on ﬁbronectin-coated Softwell hydrogels (50 kPa).
NF#1 cells (immortalized normal mouse mammary ﬁbroblasts)22 were additionally
supplemented with 1% ITS. Cells ectopically expressing mouse Wnt7a were
generated by infection with pHIV-Wnt7a-RFP lentivirus. Brieﬂy, pDEST/pHIV-
H2BmRFP-rfa_verB-Wnt7a vector plasmid, packaging plasmid psPAX2 and
envelope plasmid pMD2.G were co-transfected into HEK293T cells using
Lipofectamine 2000. Virus particles were collected and used to infect the cells.
RFP-expressing cells were selected by FACSorting. To establish stable knockdown
of Wnt7a in 4T1 cells, cells were infected with Mission particles (Sigma) containing
one of two independent Wnt7a shRNA (shWnt7a-88, TRCN0000071788 and
shWnt7a-91, TRCN0000071791) or control shRNA (shCont; SHC001V) at an
multiplicity of infection of 2. Infected cells were selected using puromycin (Sigma)
at 2.5 mgml 1 for 5–7 days.
For in vitro assays, cells were starved overnight in serum-free Advanced DMEM
(Invitrogen) before growth factor addition. Where indicated, cells were plated on
ﬁbronectin-coated Softwell hydrogels (50 kPa) in serum-free Advanced DMEM.
For TOPﬂash assay, cells were transiently co-transfected with pCMV-Green-
Renilla and the TOPﬂash and FOPﬂash plasmids and, where indicated, the
delta-GSK plasmid was also transiently co-transfected in the mixture. Twenty-four
hours post transfection, cells were starved in serum-free Advanced DMEM
overnight and then treated with bovine serum albumin (BSA), Wnt7a or SB216763
for 24 h before measuring luciferase activity with the Dual-Glo Luciferase Assay
System (Promega).
For conditioned medium production, cells atB70% conﬂuency were washed in
serum-free medium and then incubated in serum-free medium for 48 h.
Conditioned medium was ﬁltered (0.45 mm) before use.
For cell viability assays, cells were plated at 5 102 cells per well in 96-well
plates. The following day, the medium was replaced with DMEM plus 2% FCS. Six
hours later, BSA or Wnt7a (100 ngml 1) was added (day 0). At the indicated time
points, medium was aspirated and cell number was measured by adding 200 ml
CellTiter-Glo.
For matrix remodelling assays, 7.5 104 ﬁbroblasts were embedded in 100 ml of
1:1 mixture of collagen I and growth factor-reduced Matrigel (BD Biosciences),
yielding ﬁnal concentrations ofB4.6 andB2.2mgml 1, respectively, and seeded
into 24-well glass bottom MatTek plates. Once the gel was set, cells were
maintained in DMEM plus 1% FCS, 1% ITS containing BSA, Wnt7a (100 ngml 1)
or TGFb1 (1 ngml 1) in the presence or absence of SB431542 (10 mM) for 72 h.
To obtain a contraction value, the gel area was measured using the Image J software
and fold contraction over control gels (BSA-treated or control vector-transfected)
was calculated. Where indicated, gels were then formalin-ﬁxed and parafﬁn-
embedded. Sections were stained for Endo180 (Mrc2) and phospho-Smad2 as
described below, and 6–10 confocal images per gel were collected. Where indicated,
Wnt7a or conditioned media were pre-absorbed with a neutralizing anti-TGFb
antibody before use as follows. Neutralizing anti-TGFb antibody (1D11, R&D
Systems) was incubated with Protein G Dynabeads for 15min at room temperature
with rotation. Beads were washed twice and incubated with recombinant Wnt7a
(100 ngml 1) or conditioned media for 1 h at room temperature with rotation.
Beads were removed by magnetic separation and the supernatant added to the
contraction gel assays.
Organotypic invasion assays were undertaken as described previously22. In
brief, 1 106 ﬁbroblasts were embedded in a mixture of collagen I/growth
factor-reduced Matrigel matrix. After the gel was set at 37 C for 1 h, DMEM plus
10% FCS and 1% ITS was added. Sixteen hours later, 5 105 4T1 cells were seeded
on top in DMEM plus 10% FCS and 1% ITS. After 8 h, a thin layer of gel was added
covering the tumour cells. The gel was then mounted on a metal bridge and fed
from underneath with DMEM plus 10% FCS and 1% ITS (changed daily). After 6
days, the cultures were ﬁxed using 4% paraformaldehyde plus 0.25% glutaraldehyde
in PBS and processed by standard methods for haematoxylin and eosin staining.
For assays involving the removal of ﬁbroblasts (ﬁbroblast-conditioned matrix), the
ﬁbroblasts were left to remodel the gel for 5 days, after which the gels were
incubated in DMEM plus 10% FCS and 1% ITS plus hygromycin (400 mgml 1) for
48 h to kill the ﬁbroblasts and then washed three times with DMEM plus 10% FCS
and 1% ITS (430min per wash). Then, 5 105 4T1 cells were plated on top and
the assays proceeded as usual.
qPCR. Quantitative real-time RT–PCR (qRT–PCR) was performed using 5–12.5 ng
cDNA per well with 0.5 ml Taqman Gene Expression Assay probe and 5 ml qPCR
MasterMix in a 10-ml reaction volume on an ABI Prism 7900HT sequence
detection system. Each reaction was performed in triplicate. Data analysis was
performed using the SDS 2.2.1 software (Applied Biosystems). Fold change was
determined in relative quantiﬁcation units using B2m/B2M for normalization.
In vivo assays. For growth factor treatment, the 4T07 tumour cell suspension was
supplemented with recombinant growth factors before inoculation of 5 105
tumour cells suspended in 50 ml of a 1:1 mixture of PBS and growth factor-reduced
Matrigel bilaterally into the fourth mammary fat pad of 6–8-week-old female
wild-type Balb/c mice. Growth factors were injected three times per week in 50 ml
of PBS into the fourth mammary fat pad, or directly into the centre of the tumour
when tumours were palpable. Concentrations of recombinant proteins were as
follows: BMP-7, 100 ngml 1; CXCL16, 500 ngml 1; Dhh, 1 mgml 1; GM-CSF,
50 ngml 1; PDGF-BB, 300 ngml 1; Wnt7a, 100 ngml 1; and TGFb1,
1 ngml 1. Tumour volume was monitored from day 7 onwards. The experiment
was terminated when tumour size of the ﬁrst mouse reached the maximum average
diameter of 12mm.
Overall, 3 106 168FARN-Wnt7a or 168FARN-Vec cells were suspended in
100 ml of a 1:1 mixture of PBS and growth factor-reduced Matrigel and inoculated
into 6–8-week-old female Balb/c mice. Overall, 2 106 ZR75.1-Wnt7a or ZR75.1-
Vec cells were suspended in 100 ml of PBS and inoculated into 6–8-week-old female
CB17 nonobese diabetic severe combined immunodeﬁcient mice. For experimental
metastasis, 2.5 105 4T07-Wnt7a or 4T07-Vec cells were injected into the tail vein
of 6–8-week-old female Balb/c mice. For spontaneous metastasis, 1 104 4T1-
shWnt7a or 4T1-shCONT cells were inoculated into the fourth mammary fat pad
of 6–8-week-old female Balb/c mice. Tumour volumes were measured until they
reached maximum allowable size when the animals were killed (day 26) and the
lungs removed at necroscopy.
Immunostaining of mouse tumours and matrix remodelling gels. Formalin-
ﬁxed, parafﬁn-embedded tumour or matrix remodelling gel sections were stained
with antibodies against endosialin51, aSMA and endomucin, antibodies against the
pan-ﬁbroblast marker Endo180 (Mrc2)53,54 and phospho-Smad2 or antibodies
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against FAP and aSMA and were imaged with confocal laser scanning
microscopy55. Phospho-Smad2 staining in the ﬁbroblast (Endo180-positive) nuclei
was scored as 1 (negative), 2 (low) and 3 (strong). Alternatively, sections were
subjected to aSMA immunohistochemistry and HRP staining was quantiﬁed using
Image J.
Clinical material. The Breakthrough TMA has been previously described56. In
brief, following ethical approval (RMH REC), the TMA was constructed with
replicate 0.6-mm cores of invasive breast carcinomas from patients diagnosed and
treated at the Royal Marsden NHS Foundation Trust between 1994 and 2000. The
Leeds TMA including patient characteristics has been previously described11. In
brief, following ethical approval (Leeds (East) REC:06/Q1206/180), the TMA was
assembled with triplicate cores from 358 cases of breast cancer diagnosed at the
Leeds Teaching Hospitals NHS Trust between 1987 and 2005. TMAs were stained
with anti-aSMA (clone 1A4, 1:500 dilution) or anti-Wnt7a (1:200 dilution)
followed by HRP-conjugated secondary antibodies. Bound antibodies were
visualized using diaminobenzidine (EnVision, Dako) before counterstaining with
haematoxylin. All TMA scoring was performed blind. Wnt7a protein expression in
the tumour cells was scored as negative/low or high. Fibroblast activation
score¼ (ﬁbroblast abundance ﬁbroblast aSMA expression) where ﬁbroblast
abundance was scored as 1 (few ﬁbroblasts) or 2 (abundant ﬁbroblasts) and
ﬁbroblast aSMA expression was scored as 1 (none/little), 2 (intermediate) or 3
(strong). Scores across the triplicate cores were averaged.
Statistical and bioinformatics analyses. The Graphpad Prism version 6.0c
statistical package was used for statistical analysis, except for multivariate analysis
of clinical data where SPSS was used. Numerical data are expressed as
mean±s.e.m. Experiments were analysed with unpaired Student’s t-test. All tests
were two-tailed, with a conﬁdence interval of 95%. Where more than two
groups were compared, one-way ANOVA followed by Bonferroni post-test with
conﬁdence interval of 95% was used. Where more than one group with or without
inhibitor or tumour growth curves were compared, two-way ANOVA followed
by Bonferroni post-test with conﬁdence interval of 95% was used. *Po0.05;
**Po0.01; ***Po0.001.
Bioinformatic analysis of gene expression proﬁling data is described above.
Clinical relevance of variable WNT7A expression was assessed using publicly
available data from ref. 57. For survival analysis, the highest quartile of gene
expression was used to dichotomize the 533 systemically untreated breast tumours
into high and low groups.
For correlation of Wnt7a expression with the Chang et al.37 F-CSR signature,
the F-CSR signature was retrieved from http://changlab.stanford.edu/2005-PNAS-
Data.html. In the NKI295 data set, 442 probes representing 380 out of the 459
F-CSR genes were present, of which 212 probes were serum-induced with centroid
values 40, and 230 probes were serum-repressed with centroid values o0. Gene
expression of the 442 probes from NKI295 data set was used to calculate a module
score for each sample. The module scored is a weighted averaging58
(Supplementary Fig. 8b).
For correlation of Wnt7a expression with the Calon et al.38 F-TBRS, the
F-TBRS signature was retrieved from http://dx.doi.org/10.1016/j.ccr.2012.08.013.
There were 286 probes representing 171 unique annotated genes. In the TCGA
data set 151 out of the 171 F-TBRS genes were matched. Average gene expressions
of the 151 genes from TCGA data set was used as the signature score for each
tumour. WNT7A gene expression was signiﬁcantly correlated with F-TBRS
signature (r¼ 0.123, P¼ 0.005) using Pearson correlation in the 522 primary
breast cancer of the TCGA data set for which gene expression data were available
(http://tcga-data.nci.nih.gov/docs/publications/brca_2012/BRCA.exp.547.med.txt).
For correlation of Wnt7a expression with the Finak et al.39 SDPP, the SDPP was
retrieved from GeneSigDB (http://compbio.dfci.harvard.edu/genesigdb/). The
SDPP contains 26 genes, of which 10 are associated with good patient prognosis, 10
with mixed prognosis and 6 with poor prognosis. In the TCGA data set of 522
primary breast cancers, unsupervised hierarchical clustering (Pearson correlation
distance, Ward cluster method) was performed using the mapped median-centred
gene expression. WNT7A clustered together with the SDPP poor-prognosis genes
(Fig. 8e). Pearson correlation resulted in a signiﬁcant association between WNT7A
gene expressions with centroid values of poor-prognosis genes (r¼ 0.213, adjusted
Po0.0001).
References
1. De Wever, O., Demetter, P., Mareel, M. & Bracke, M. Stromal myoﬁbroblasts
are drivers of invasive cancer growth. Int. J. Cancer 123, 2229–2238 (2008).
2. Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 6, 392–401
(2006).
3. Pietras, K. & Ostman, A. Hallmarks of cancer: interactions with the tumour
stroma. Exp. Cell Res. 316, 1324–1331 (2010).
4. Schafer, M. & Werner, S. Cancer as an overhealing wound: an old hypothesis
revisited. Nat. Rev. Mol. Cell Biol. 9, 628–638 (2008).
5. Cirri, P. & Chiarugi, P. Cancer-associated-ﬁbroblasts and tumour cells: a
diabolic liaison driving cancer progression. Cancer Metastasis Rev. 31, 195–208
(2012).
6. Cardone, A., Tolino, A., Zarcone, R., Borruto Caracciolo, G. & Tartaglia, E.
Prognostic value of desmoplastic reaction and lymphocytic inﬁltration in the
management of breast cancer. Panminerva Med. 39, 174–177 (1997).
7. Paraiso, K. H. & Smalley, K. S. Fibroblast-mediated drug resistance in cancer.
Biochem. Pharmacol. 85, 1033–1041 (2013).
8. Ohlund, D., Elyada, E. & Tuveson, D. Fibroblast heterogeneity in the cancer
wound. J. Exp. Med. 211, 1503–1523 (2014).
9. Sugimoto, H., Mundel, T. M., Kieran, M. W. & Kalluri, R. Identiﬁcation of
ﬁbroblast heterogeneity in the tumour microenvironment. Cancer Biol. Ther. 5,
1640–1646 (2006).
10. Paulsson, J. et al. Prognostic signiﬁcance of stromal platelet-derived growth
factor beta-receptor expression in human breast cancer. Am. J. Pathol. 175,
334–341 (2009).
11. Simpkins, S. A., Hanby, A. M., Holliday, D. L. & Speirs, V. Clinical and
functional signiﬁcance of loss of caveolin-1 expression in breast cancer-
associated ﬁbroblasts. J. Pathol. 227, 490–498 (2012).
12. Busch, S., Ryden, L., Stal, O., Jirstrom, K. & Landberg, G. Low ERK
phosphorylation in cancer-associated ﬁbroblasts is associated with tamoxifen
resistance in pre-menopausal breast cancer. PLoS ONE 7, e45669 (2012).
13. Aslakson, C. J., McEachern, D., Conaway, D. H. & Miller, F. R. Inhibition of
lung colonization at two different steps in the metastatic sequence. Clin. Exp.
Metastasis 9, 139–150 (1991).
14. Aslakson, C. J. & Miller, F. R. Selective events in the metastatic process deﬁned
by analysis of the sequential dissemination of subpopulations of a mouse
mammary tumour. Cancer Res. 52, 1399–1405 (1992).
15. Miller, F. R., Miller, B. E. & Heppner, G. H. Characterization of metastatic
heterogeneity among subpopulations of a single mouse mammary tumour:
heterogeneity in phenotypic stability. Invasion Metastasis 3, 22–31 (1983).
16. MacFadyen, J. R. et al. Endosialin (TEM1, CD248) is a marker of stromal
ﬁbroblasts and is not selectively expressed on tumour endothelium. FEBS Lett.
579, 2569–2575 (2005).
17. Simonavicius, N. et al. Endosialin (CD248) is a marker of tumour-associated
pericytes in high-grade glioma. Mod. Pathol. 21, 308–315 (2008).
18. Untergasser, G. et al. Proﬁling molecular targets of TGF-beta1 in prostate
ﬁbroblast-to-myoﬁbroblast transdifferentiation. Mech. Ageing Dev. 126, 59–69
(2005).
19. Hawinkels, L. J. et al. Interaction with colon cancer cells hyperactivates
TGF-beta signaling in cancer-associated ﬁbroblasts. Oncogene 33, 97–107
(2012).
20. Kojima, Y. et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1)
signaling drives the evolution of tumour-promoting mammary stromal
myoﬁbroblasts. Proc. Natl Acad. Sci. USA 107, 20009–20014 (2010).
21. Van Obberghen-Schilling, E., Roche, N. S., Flanders, K. C., Sporn, M. B. &
Roberts, A. B. Transforming growth factor beta 1 positively regulates its own
expression in normal and transformed cells. J. Biol. Chem. 263, 7741–7746
(1988).
22. Calvo, F. et al. Mechanotransduction and YAP-dependent matrix remodelling
is required for the generation and maintenance of cancer-associated ﬁbroblasts.
Nat. Cell Biol. 15, 637–646 (2013).
23. Cygan, J. A., Johnson, R. L. & McMahon, A. P. Novel regulatory interactions
revealed by studies of murine limb pattern in Wnt-7a and En-1 mutants.
Development 124, 5021–5032 (1997).
24. Hall, A. C., Lucas, F. R. & Salinas, P. C. Axonal remodeling and synaptic
differentiation in the cerebellum is regulated by WNT-7a signaling. Cell 100,
525–535 (2000).
25. Parr, B. A. & McMahon, A. P. Dorsalizing signal Wnt-7a required for
normal polarity of D-V and A-P axes of mouse limb. Nature 374, 350–353
(1995).
26. Miyoshi, H., Ajima, R., Luo, C. T., Yamaguchi, T. P. & Stappenbeck, T. S.
Wnt5a potentiates TGF-beta signaling to promote colonic crypt regeneration
after tissue injury. Science 338, 108–113 (2012).
27. Bentzinger, C. F. et al. Fibronectin regulates wnt7a signaling and satellite cell
expansion. Cell Stem Cell 12, 75–87 (2013).
28. Moreno-Estelles, M. et al. Symmetric expansion of neural stem cells from the
adult olfactory bulb is driven by astrocytes via WNT7A. Stem Cells 30,
2796–2809 (2012).
29. Carmon, K. S. & Loose, D. S. Secreted frizzled-related protein 4 regulates two
Wnt7a signaling pathways and inhibits proliferation in endometrial cancer
cells. Mol. Cancer Res. 6, 1017–1028 (2008).
30. Yoshioka, S. et al.WNT7A regulates tumour growth and progression in ovarian
cancer through the WNT/beta-catenin pathway. Mol. Cancer Res. 10, 469–482
(2012).
31. Lyu, J. & Joo, C. K. Wnt-7a up-regulates matrix metalloproteinase-12
expression and promotes cell proliferation in corneal epithelial cells during
wound healing. J. Biol. Chem. 280, 21653–21660 (2005).
32. Le Grand, F., Jones, A. E., Seale, V., Scime, A. & Rudnicki, M. A. Wnt7a
activates the planar cell polarity pathway to drive the symmetric expansion of
satellite stem cells. Cell Stem Cell 4, 535–547 (2009).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10305 ARTICLE
NATURE COMMUNICATIONS | 7:10305 | DOI: 10.1038/ncomms10305 | www.nature.com/naturecommunications 13
33. Ciani, L. et al. Wnt7a signaling promotes dendritic spine growth and synaptic
strength through Ca(2)(þ )/Calmodulin-dependent protein kinase II. Proc.
Natl Acad. Sci. USA 108, 10732–10737 (2011).
34. Bierie, B. & Moses, H. L. TGF-beta and cancer. Cytokine Growth Factor Rev. 17,
29–40 (2006).
35. Desmouliere, A., Geinoz, A., Gabbiani, F. & Gabbiani, G. Transforming growth
factor-beta 1 induces alpha-smooth muscle actin expression in granulation
tissue myoﬁbroblasts and in quiescent and growing cultured ﬁbroblasts. J. Cell
Biol. 122, 103–111 (1993).
36. Lewis, M. P. et al. Tumour-derived TGF-beta1 modulates myoﬁbroblast
differentiation and promotes HGF/SF-dependent invasion of squamous
carcinoma cells. Br. J. Cancer 90, 822–832 (2004).
37. Chang, H. Y. et al. Robustness, scalability, and integration of a wound-response
gene expression signature in predicting breast cancer survival. Proc. Natl Acad.
Sci. USA 102, 3738–3743 (2005).
38. Calon, A. et al. Dependency of colorectal cancer on a TGF-beta-driven program
in stromal cells for metastasis initiation. Cancer Cell 22, 571–584 (2012).
39. Finak, G. et al. Stromal gene expression predicts clinical outcome in breast
cancer. Nat. Med. 14, 518–527 (2008).
40. Eckhardt, B. L. et al. Genomic analysis of a spontaneous model of breast cancer
metastasis to bone reveals a role for the extracellular matrix.Mol. Cancer Res. 3,
1–13 (2005).
41. Lou, Y. et al. Epithelial-mesenchymal transition (EMT) is not sufﬁcient for
spontaneous murine breast cancer metastasis. Dev. Dyn. 237, 2755–2768 (2008).
42. Yang, J. et al. Twist, a master regulator of morphogenesis, plays an essential role
in tumour metastasis. Cell 117, 927–939 (2004).
43. Attisano, L. & Wrana, J. L. Signal integration in TGF-beta, WNT, and Hippo
pathways. F1000prime Rep. 5, 17 (2013).
44. Attisano, L. & Labbe, E. TGFbeta and Wnt pathway cross-talk. Cancer
Metastasis Rev. 23, 53–61 (2004).
45. Kumawat, K. et al. Noncanonical WNT-5A signaling regulates TGF-beta-
induced extracellular matrix production by airway smooth muscle cells. FASEB
J. 27, 1631–1643 (2013).
46. Akhmetshina, A. et al. Activation of canonical Wnt signalling is required for
TGF-beta-mediated ﬁbrosis. Nat. Commun. 3, 735 (2012).
47. Miyoshi, H. & Stappenbeck, T. S. Counteracting stem cell expansion during
wound repair: distinct roles of non-canonical Wnt and TGF-beta. Cell Cycle 12,
387–388 (2013).
48. Gough, N. R. Focus issue: an expanding world for TGF-beta signaling. Sci.
Signal. 1, eg8 (2008).
49. Ren, S. et al. LRP-6 is a coreceptor for multiple ﬁbrogenic signaling pathways in
pericytes and myoﬁbroblasts that are inhibited by DKK-1. Proc. Natl Acad. Sci.
USA 110, 1440–1445 (2013).
50. Ishiguro, K. et al. Syndecan-4 deﬁciency leads to high mortality of
lipopolysaccharide-injected mice. J. Biol. Chem. 276, 47483–47488 (2001).
51. MacFadyen, J., Savage, K., Wienke, D. & Isacke, C. M. Endosialin is expressed
on stromal ﬁbroblasts and CNS pericytes in mouse embryos and is
downregulated during development. Gene Expr. Patterns 7, 363–369 (2007).
52. Schaefer, B. C., Schaefer, M. L., Kappler, J. W., Marrack, P. & Kedl, R. M.
Observation of antigen-dependent CD8þ T-cell/ dendritic cell interactions
in vivo. Cell Immunol. 214, 110–122 (2001).
53. Curino, A. C. et al. Intracellular collagen degradation mediated by uPARAP/
Endo180 is a major pathway of extracellular matrix turnover during
malignancy. J. Cell Biol. 169, 977–985 (2005).
54. Isacke, C. M., van der Geer, P., Hunter, T. & Trowbridge, I. S. p180, a novel
recycling transmembrane glycoprotein with restricted cell type expression. Mol.
Cell Biol. 10, 2606–2618 (1990).
55. Robertson, D., Savage, K., Reis-Filho, J. & Isacke, C. Multiple
immunoﬂuorescence labelling of formalin-ﬁxed parafﬁn-embedded (FFPE)
tissue. BMC Cell Biol. 9, 13 (2008).
56. Reis-Filho, J. S. et al. Distribution and signiﬁcance of nerve growth factor
receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod.
Pathol. 19, 307–319 (2006).
57. Gyorffy, B., Lanczky, A. & Szallasi, Z. Implementing an online tool for
genome-wide validation of survival-associated biomarkers in ovarian-cancer
using microarray data from 1287 patients. Endocr. Relat. cancer 19, 197–208
(2012).
58. Loi, S. et al. PIK3CA mutations associated with gene signature of low mTORC1
signaling and better outcomes in estrogen receptor-positive breast cancer. Proc.
Natl Acad. Sci. USA 107, 10208–10213 (2010).
Acknowledgements
This work was funded by Breakthrough Breast Cancer (recently merged with Breast
Cancer Campaign forming Breast Cancer Now; C.M.I.), Cancer Research UK (A.A., E.S.
and CMI) and Breast Cancer Campaign (V.S. and A.H.). F.C. is currently funded by
The Institute of Cancer Research and Worldwide Cancer Research. We acknowledge
NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden and
the ICR. We thank the Breakthrough Histopathology Facility, Cambridge Genomic
Services for the gene expression analysis, Balazs Gyorffy for providing the clinical
breast cancer outcome data, Antoinette van Weverwijk for help with the in vivo
assays, Fredrik Wallberg for help with the FACSorting, Andrea Morandi for help
with the TMA analysis, Patricia Salinas for the Wnt7a cDNA construct and helpful
discussions and Lorenzo Melchor for the pDEST/pHIV-H2BmRFP-rfa_verB Gateway
cloning vector.
Author contributions
A.A., M.I., P.K., E.S., F.C. and C.M.I. designed the experiments. A.A., M.I., D.R.,
A.F., F.C. and C.M.I. performed in vitro experiments, tumour staining and tumour
scoring, A.A., A.F. and M.I. performed in vivo experiments, A.M.H. and V.S. provided
the Leeds TMA, associated clinical data and outcome analysis, Q.G. performed
bioinformatics analysis, A.A., M.I. and C.M.I. wrote the manuscript with input from
all authors.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Avgustinova, A. et al. Tumour cell-derived Wnt7a recruits and
activates ﬁbroblasts to promote tumour aggressiveness. Nat. Commun. 7:10305
doi: 10.1038/ncomms10305 (2016).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10305
14 NATURE COMMUNICATIONS | 7:10305 | DOI: 10.1038/ncomms10305 | www.nature.com/naturecommunications
